Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 3
1984 3
1985 4
1986 4
1987 5
1988 3
1989 4
1990 7
1991 6
1992 8
1993 5
1994 15
1995 19
1996 24
1997 20
1998 18
1999 19
2000 30
2001 25
2002 56
2003 77
2004 59
2005 53
2006 59
2007 54
2008 56
2009 92
2010 80
2011 94
2012 66
2013 76
2014 80
2015 83
2016 132
2017 152
2018 126
2019 128
2020 185
2021 175
2022 165
2023 138
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

2,210 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Alzheimer disease 17"
Page 1
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials.
Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade RD, Cummings JL. Grossberg GT, et al. Am J Geriatr Psychiatry. 2020 Apr;28(4):383-400. doi: 10.1016/j.jagp.2019.09.009. Epub 2019 Oct 1. Am J Geriatr Psychiatry. 2020. PMID: 31708380 Free article. Clinical Trial.
OBJECTIVE: To assess the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer's dementia (AAD). DESIGN: Two 12-week, randomized, double-blind, placebo-controlled, parallel-arm studies (NCT01862640; NCT01922258). ...Stable Al …
OBJECTIVE: To assess the efficacy, safety, and tolerability of brexpiprazole in patients with agitation in Alzheimer's dementia (AAD) …
Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
Mühlbauer V, Möhler R, Dichter MN, Zuidema SU, Köpke S, Luijendijk HJ. Mühlbauer V, et al. Cochrane Database Syst Rev. 2021 Dec 17;12(12):CD013304. doi: 10.1002/14651858.CD013304.pub2. Cochrane Database Syst Rev. 2021. PMID: 34918337 Free PMC article. Review.
Two review authors independently screened the title and abstract of the hits, and two review authors assessed the full text of studies that got through this screening. SELECTION CRITERIA: We included randomised, placebo-controlled, parallel-arm trials comparing the effects …
Two review authors independently screened the title and abstract of the hits, and two review authors assessed the full text of studies that …
The efficacy and safety of memantine for the treatment of Alzheimer's disease.
Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T, Iwata N. Matsunaga S, et al. Expert Opin Drug Saf. 2018 Oct;17(10):1053-1061. doi: 10.1080/14740338.2018.1524870. Epub 2018 Sep 26. Expert Opin Drug Saf. 2018. PMID: 30222469 Review.
Currently, five pharmacotherapeutic options are available to treat Alzheimer's disease: memantine; the three cholinesterase inhibitors donepezil, galantamine, and rivastigmine; and combination treatments with memantine and one cholinesterase inhibitor. ...Therefore, …
Currently, five pharmacotherapeutic options are available to treat Alzheimer's disease: memantine; the three cholinesterase in …
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.
Vossel K, Ranasinghe KG, Beagle AJ, La A, Ah Pook K, Castro M, Mizuiri D, Honma SM, Venkateswaran N, Koestler M, Zhang W, Mucke L, Howell MJ, Possin KL, Kramer JH, Boxer AL, Miller BL, Nagarajan SS, Kirsch HE. Vossel K, et al. JAMA Neurol. 2021 Nov 1;78(11):1345-1354. doi: 10.1001/jamaneurol.2021.3310. JAMA Neurol. 2021. PMID: 34570177 Free PMC article. Clinical Trial.
IMPORTANCE: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). OBJECTIVE: To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD. DESIGN, SETTING, AND PARTICIPANT …
IMPORTANCE: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). OBJECTI …
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.
BACKGROUND: Monoclonal antibodies that target amyloid-beta (Abeta) have the potential to slow cognitive and functional decline in persons with early Alzheimer's disease. Gantenerumab is a subcutaneously administered, fully human, anti-Abeta IgG1 monoclonal antibody …
BACKGROUND: Monoclonal antibodies that target amyloid-beta (Abeta) have the potential to slow cognitive and functional decline in persons wi …
Can We Use Ginkgo biloba Extract to Treat Alzheimer's Disease? Lessons from Preclinical and Clinical Studies.
Xie L, Zhu Q, Lu J. Xie L, et al. Cells. 2022 Jan 29;11(3):479. doi: 10.3390/cells11030479. Cells. 2022. PMID: 35159288 Free PMC article. Review.
Accumulating evidence has revealed the therapeutic potential of GBE against Alzheimer's disease (AD); however, no systematic evaluation has been performed; (2) Methods: a total of 17 preclinical studies and 20 clinical trials assessing the therapeutic …
Accumulating evidence has revealed the therapeutic potential of GBE against Alzheimer's disease (AD); however, no systematic e …
Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer's disease markers in subjects with mild cognitive impairment.
Nagpal R, Neth BJ, Wang S, Craft S, Yadav H. Nagpal R, et al. EBioMedicine. 2019 Sep;47:529-542. doi: 10.1016/j.ebiom.2019.08.032. Epub 2019 Aug 30. EBioMedicine. 2019. PMID: 31477562 Free PMC article.
BACKGROUND: Alzheimer's disease (AD) prevalence is increasing, but its etiology remains elusive. ...Herein, we examine how the gut microbiome differs in older adults with mild cognitive impairment compared to cognitively normal counterparts, and whether and how a mo …
BACKGROUND: Alzheimer's disease (AD) prevalence is increasing, but its etiology remains elusive. ...Herein, we examine how the …
Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.
Babiloni C, Arakaki X, Azami H, Bennys K, Blinowska K, Bonanni L, Bujan A, Carrillo MC, Cichocki A, de Frutos-Lucas J, Del Percio C, Dubois B, Edelmayer R, Egan G, Epelbaum S, Escudero J, Evans A, Farina F, Fargo K, Fernández A, Ferri R, Frisoni G, Hampel H, Harrington MG, Jelic V, Jeong J, Jiang Y, Kaminski M, Kavcic V, Kilborn K, Kumar S, Lam A, Lim L, Lizio R, Lopez D, Lopez S, Lucey B, Maestú F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Noce G, Olichney J, Onofrj M, Osorio R, Parra-Rodriguez M, Rajji T, Ritter P, Soricelli A, Stocchi F, Tarnanas I, Taylor JP, Teipel S, Tucci F, Valdes-Sosa M, Valdes-Sosa P, Weiergräber M, Yener G, Guntekin B. Babiloni C, et al. Alzheimers Dement. 2021 Sep;17(9):1528-1553. doi: 10.1002/alz.12311. Epub 2021 Apr 15. Alzheimers Dement. 2021. PMID: 33860614 Free PMC article. Review.
The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalography (EEG) measures for Alzheimer's disease (AD) clinical trials. The Panel reviewed the field literature. As most cons …
The Electrophysiology Professional Interest Area (EPIA) and Global Brain Consortium endorsed recommendations on candidate electroencephalogr …
Clinical Trials of New Drugs for Vascular Cognitive Impairment and Vascular Dementia.
Linh TTD, Hsieh YC, Huang LK, Hu CJ. Linh TTD, et al. Int J Mol Sci. 2022 Sep 21;23(19):11067. doi: 10.3390/ijms231911067. Int J Mol Sci. 2022. PMID: 36232368 Free PMC article. Review.
Vascular dementia is the second leading cause of dementia after Alzheimer's disease. Cognitive consequences after ischemic brain injury have been recognized as a preferred target for therapeutic strategies, prompting the search for potential agents. ...The agents we …
Vascular dementia is the second leading cause of dementia after Alzheimer's disease. Cognitive consequences after ischemic bra …
Study protocol for the Alzheimer and music therapy study: An RCT to compare the efficacy of music therapy and physical activity on brain plasticity, depressive symptoms, and cognitive decline, in a population with and at risk for Alzheimer's disease.
Flo BK, Matziorinis AM, Skouras S, Sudmann TT, Gold C, Koelsch S. Flo BK, et al. PLoS One. 2022 Jun 30;17(6):e0270682. doi: 10.1371/journal.pone.0270682. eCollection 2022. PLoS One. 2022. PMID: 35771851 Free PMC article.
BACKGROUND: There is anecdotal evidence for beneficial effects of music therapy in patients with Alzheimer's Disease (AD). However, there is a lack of rigorous research investigating this issue. ...DISCUSSION: Addressing the need for rigorous longitudinal data for t …
BACKGROUND: There is anecdotal evidence for beneficial effects of music therapy in patients with Alzheimer's Disease (AD). How …
2,210 results